$MDLN

CORCORAN JESSI L purchased $171K of MDLN

CORCORAN JESSI L (Principal Accounting Officer) purchased 5,000 shares of Medline Inc. (MDLN) at $34.15 ($0.17M total) on 2026-06-05.

Original reporting
SEC EDGAR · CORCORAN JESSI L
Published Jun 9, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDLN
Bullish
medium confidence
Mentioned
$MDLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDLNBullishLow
01

Why it matters

This adds a fresh, primary-source datapoint on insider buying, but it does not include operational, financial, or regulatory catalysts.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to drive a major repricing without corroborating fundamental news.

03

What to watch

The article provides only the transaction details (size/price/date) and no accompanying narrative on why the purchase occurred or whether other insiders/large holders acted.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-09 (covers buy dated 2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Medline Inc.

Company-level read

Ticker impact

$MDLNBullishMedium confidence
Context

Medline insider (principal accounting officer) bought 5,000 shares in an open-market transaction at $34.15 on 2026-06-05 (Form 4).

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but the disclosed size (~$171k) and lack of 10b5-1 plan detail reduce the signal strength for trading decisions.

Market effects

No sector-wide read-through; this is a company-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related and may not reflect a change in business outlook; without a 10b5-1 plan, interpretation is still uncertain.

Key entities

  • Medline Inc.

    Subject of the Form 4 insider transaction disclosure (MDLN).

  • CORCORAN JESSI L

    Principal Accounting Officer who purchased shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDLNMed

Medline rises as investors weigh new customer wins and post-earnings reset

Medline Inc. (MDLN) shares rose 3.2% after announcing new customer wins, including expanded agreements with Stillwater Medical Center and Ohio County Healthcare. The company reported 11.6% sales growth in Q2 but lowered full-year EBITDA guidance. Analysts have mixed price targets, with a median of $53.0. Insider trading shows mostly sales, while hedge funds have varied positions.

Med

Medline Adds Customers, Distribution Capacity as Sales Rise 11.6%

Medline reported Q2 sales up 11.6% to $7.685B and net income down 58.3% to $139M, citing $336M fire-related losses tied to its Tracy, California distribution center. For 1H 2026, sales rose 11.1% to $15.037B. Medline said it signed over $650M in new customer business and is adding distribution centers, automation, and workers, including California capacity expansion to about 5M sq ft by mid-2027.

$MDLNMed

Medline (MDLN) Q2 2026 Earnings Call Transcript

Medline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.

$MDLNMed

Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products - Medline (NASDA

Medline said regulatory guidance followed its corrective actions for surgical convenience kits whose components were affected by a Becton Dickinson recall. The alert cites BD lot 4032183 ChloraPrep Clear 1 mL and lot 4073005 FREPP Clear 1.5 mL applicators, with compromised sterile seals and possible Aspergillus contamination. Medline reported no severe injuries or deaths as of Aug 3. MDLN shares were $35.71, up 0.61%.